|
October 26, 2021
|
Progenity Reduces Outstanding Debt by $20.175 Million Through a Private Exchange of $20.175 Million of Its 7.25% Convertible Senior Notes Due 2025 for Shares of Common Stock
|
|
October 19, 2021
|
Progenity to Participate in Crohn’s & Colitis Foundation’s Fourth Annual IBD Innovate Conference
|
|
October 13, 2021
|
Progenity Announces Several Patents Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Ingestible Therapeutics Technologies
|
|
October 6, 2021
|
Progenity Announces Closing of $20 Million Registered Direct Offering of Common Stock Priced at Premium to Market Under Nasdaq Rules
|
|
October 4, 2021
|
Progenity Announces $20 Million Registered Direct Offering of Common Stock Priced at Premium to Market Under Nasdaq Rules
|
|
September 21, 2021
|
Progenity to Participate in 11th Annual Partnership Opportunities in Drug Delivery Conference
|
|
September 14, 2021
|
Progenity Announces Patent Granted by USPTO for its Preeclampsia Rule-Out Test
|
|
September 3, 2021
|
Progenity to Participate in Two Upcoming Investor Conferences
|
|
August 24, 2021
|
Progenity Announces Closing of $40 Million Underwritten Public Offering
|
|
August 19, 2021
|
Progenity Announces Pricing of $40 Million Public Offering of Common Stock and Warrants
|